Analysis for Life

Manufactures handheld mass spectroscopy instruments for chemical and biomolecular analysis for the field forensics and bioprocessing sectors.


Life sciences tools

Partner since

April 2019
908 Devices logo and an instrument

Sands Capital first partnered with 908 Devices through its Series E round in April 2019. We assisted the company in securing investors for this round. Our team has continued to counsel management on forming strategic relationships and navigating the IPO process.

The case studies provided herein are a selection of investments that we believe illustrate our investment approach and philosophy, as well as the range of businesses in which Sands Capital typically invests. They were selected on an objective basis. The case studies are being provided for discussion purposes only and the information included should not be relied upon to make any investment decision. The full portfolio holdings are available here.

Related Insights

Eight Cybersecurity Trends to Watch in 2024
Healthcare Technology Trends for 2023
Connecting Brands with Digital Content Creators
As AI/ML Models Become More Prevalent, So Too Must Risk Management